Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications - Takeaways - MDSpire

Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications

  • By

  • Fanyuan Wu

  • Quezhu Danzeng

  • Runxi Wu

  • Yi Shen

  • Guang Shi

  • May 20, 2026

  • 0 min

Share

  • 1

    Endogenous retroviruses (ERVs) comprise approximately 8% of the human genome and are remnants of ancient retroviral integrations.

  • 2

    ERV reactivation in cancer can lead to the production of immunogenic proteins and double-stranded RNA, enhancing immune responses.

  • 3

    Clinical studies suggest that ERV signatures may serve as biomarkers for immune checkpoint inhibitor response, independent of PD-L1.

  • 4

    Therapeutic strategies targeting ERVs could sensitize tumors to immune checkpoint inhibitors, though challenges in validation remain.

  • 5

    ERVs play a dual role in immune regulation, maintaining baseline immune activity while preventing inappropriate immune responses.

Original Source(s)

Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications

  • by Fanyuan Wu, Quezhu Danzeng, Runxi Wu, Yi Shen, Guang Shi

  • May 20, 2026

Related Content

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer